As the most common stem cell type being used within regenerative medicine, there is huge potential for growth within the mesenchymal stem cell (MSC) market. Today, MSCs are the most common stem cell type being used within clinical trials, as well as the most studied stem cell type within the scientific literature. [Read more…]
Only a Few Seats Left for AAOSCP’s Scientific Congress & Workshop in Miami (Aug 2-4, 2019)
Workshop features BM, SVF, UCB, Peptides, Cytokines and Exosomes under the same roof.
The American Academy of Stem Cell Physicians (AAOSCP) is hosting an August 2-4, 2019 conference that is filling up fast. With only a few seats left, medical practitioners who are seeking to learn skills and techniques for integrating regenerative medicine (RM) into their practice are encouraged to register immediately. [Read more…]
Century Therapeutics Launches With $250 Million for Allogeneic iPSC Platform
Created by Versant Ventures and partnered with Fujifilm to develop iPSC-derived adaptive and innate immune effector cell therapies
Leaps by Bayer leads investment round with USD 215 million commitment to develop next-generation immune oncology treatments
July 01, 2019, LEVERKUSEN, Germany & PHILADELPHIA & TOKYO–Century Therapeutics, which was created by Versant Ventures as part of the firm’s core strategy to launch innovative biotech companies, emerged from stealth mode today with USD 250 million in financing commitments from Bayer, Versant and Fujifilm Cellular Dynamics Inc. (FCDI). The proceeds will enable Century to advance multiple programs into the clinic for hematologic and solid malignancies. [Read more…]
Development of iPSC-derived Disease Models
Human induced pluripotent stem cell (iPSC)-based models are a valuable resource for studying disease mechanisms in vitro at the cellular level[1], screening potential new therapeutics[2], and investigating the propensity and mechanism for the development of toxic side effects caused by a drug treatment[3]. Such iPSC-based models enable research to be performed under defined experimental conditions and in a reproducible manner. [Read more…]
Hemostemix. The Canadian Biotech that Could Change Healthcare as We Know It.
Hemostemix Inc. (“Hemostemix”) (TSX Venture:HEM; OTCQB:HMTXF) is a publicly traded clinical-stage biotech company that develops and commercializes blood-derived stem cell therapies for medical conditions lacking adequate treatment options. Importantly, it is one of the first clinical-stage biotech companies to test a stem cell therapy within an international, multi-center Phase II clinical trial for patients with critical limb ischemia (“CLI”). CLI is a severe form of peripheral artery disease (“PAD”) that is caused by reduced blood flow to the extremities. After showing promising results in a Phase I trial and with a large number of historical patient treatments performed in open trials, Hemostemix’s Phase II trial targets a participant’s diseased tissue with proprietary cells grown from his or her blood that can support the formation of new blood vessels. This lead cell therapy product is called ACP-01. [Read more…]
